TechAmerica
SearchSubscribe
Cognito Alzheimer’s Trial Misses Primary Endpoint
Image credit TechAmerica.ai

Cognito Alzheimer’s Trial Misses Primary Endpoint

Cognito’s Phase 3 HOPE study missed its primary endpoint. Findings in a prespecified mild-disease subgroup suggest possible benefit, but Spectris AD remains investigational as the company prepares for FDA discussions.

The Cognito Alzheimer’s trial missed its primary endpoint, leaving the company’s investigational Spectris AD device without a positive overall efficacy result. Cognito nevertheless plans FDA discussions after a prespecified analysis suggested possible benefit among participants with mild disease.

Results from the Phase 3 HOPE study were presented Nov. 16 at the Clinical Trials on Alzheimer’s Disease conference in Boston. The findings separate two questions: whether the device worked across the study population and whether earlier-stage patients might respond differently.

What the Cognito Alzheimer’s trial tested

HOPE enrolled 673 participants with mild-to-moderate Alzheimer’s disease, with 663 included in the primary analysis. Participants received active treatment or a sham device for 12 months in a randomised, double-masked study.

Spectris delivers light and sound stimulation at 40 hertz during daily, one-hour sessions at home. The main outcome was combined scores for cognition and everyday function using the iADMARS scale. The sham comparison was intended to distinguish effects of active stimulation from changes seen with control treatment.

Cognito’s results announcement reported no statistically significant difference from sham on that primary measure. Secondary endpoints also showed no statistically significant differences across the overall analysis population.

Mild-disease findings point to a narrower research question

The prespecified mild-disease subgroup included 395 participants. MIT’s Picower Institute reported that this group showed nominally significant differences on three measures, while participants with moderate disease showed no clinical benefit.

Reported slowing of decline relative to sham in the mild subgroup was:

  • 56% on ADCS-ADL, which measures daily function.

  • 53% on ADCS-iADL, which measures instrumental activities of daily living.

  • 47% on CDR-SB, which assesses cognition and function.

These figures describe relative differences in decline, not recovery of lost abilities. The mild subgroup’s combined iADMARS score and separate cognition score did not reach nominal statistical significance.

A smaller analysis of 169 mild-disease participants who met treatment-use requirements showed larger effects. However, selecting participants by adherence can introduce bias. Those findings cannot establish that greater device use caused better outcomes.

Why the statistical distinction matters

The favourable findings from the Cognito Alzheimer’s trial used nominal p-values, which were not adjusted for multiple comparisons. Testing several outcomes creates more opportunities for an apparently positive result to occur by chance.

FDA guidance on trial endpoints explains this statistical problem and the need to control it. Although that guidance addresses drug trials, the underlying issue helps explain why individual positive comparisons require careful interpretation.

A prespecified subgroup is defined before results are examined, which strengthens the rationale for investigating it. It still does not turn a negative primary analysis into a positive overall trial. The appropriate question is whether the subgroup evidence is strong enough to support a narrower claim.

Light and sound research grew out of laboratory work

The approach originated in MIT research into stimulating brain rhythms associated with cognitive processes. Researchers investigated 40-hertz stimulation in animal models before advancing human studies.

MIT’s research update describes experiments involving amyloid, brain cells and memory in mice. Those findings supplied a biological rationale for clinical testing; they cannot establish treatment effectiveness in people.

Spectris uses external sensory stimulation, unlike the surgically placed technology described in TechAmerica’s brain sensor coverage. These approaches serve different purposes and follow different development paths, so findings from one cannot validate the other.

FDA discussions remain ahead

The Alzheimer’s Drug Discovery Foundation, which has invested in Cognito, said the mild-disease findings warrant further investigation. Its update emphasised the need to determine whether the early signals hold up as more evidence becomes available.

Cognito intends to discuss a possible authorisation pathway for early symptomatic Alzheimer’s with the FDA. Spectris AD remains investigational, with these results not establishing FDA authorisation.

The Cognito Alzheimer’s trial adds to the device research covered in TechAmerica’s Biotech & Health section. The MassDevice report focuses on the missed endpoint and the company’s shift toward early disease, while regulatory discussions remain the next proposed step.

Keshav Khandelwal

I am a technology and healthcare writer with more than four years of professional experience. Before joining TechAmerica.ai, I worked with a UK-based medical equipment company, where I gained hands-on exposure to medical devices, healthcare products, and the… All stories by Keshav

Related articles

More on Cognito Therapeutics, Alzheimer’s Disease, Spectris AD.

See More - All Biotech & Health stories

Newsletters

The day's tech news, in five minutes

Written by the reporters who cover each beat. No sponsored stories, and you can unsubscribe in one click.

Send me

By subscribing you agree to our Terms and Privacy policy.

Thank you

Your newsletter subscription has been received. Thank you for subscribing to TechAmerica.ai.